J P M Burbach1, S A Kurk2, R R J Coebergh van den Braak3, V K Dik4, A M May5, G A Meijer6, C J A Punt7, G R Vink8, M Los9, N Hoogerbrugge10, P C Huijgens8, J N M Ijzermans3, E J Kuipers11, M E de Noo12, J P Pennings13, A M T van der Velden14, C Verhoef3, P D Siersema15, M G H van Oijen7, H M Verkooijen16, M Koopman2. 1. a Radiation Oncology , UMC Utrecht , Utrecht , The Netherlands. 2. b Medical Oncology , UMC Utrecht , Utrecht , The Netherlands. 3. c Surgery , Erasmus University Medical Center , Rotterdam , The Netherlands. 4. d Gastro-Enterology , Meander Medical Center , Amersfoort , The Netherlands. 5. e Julius Center for Health Sciences and Primary Care, UMC Utrecht , Utrecht , The Netherlands. 6. f Pathology , Netherlands Cancer Institute , Amsterdam , The Netherlands. 7. g Medical Oncology , Academic Medical Center, University of Amsterdam , The Netherlands. 8. h Netherlands Comprehensive Cancer Organisation , Utrecht , The Netherlands. 9. i Medical Oncology , St. Antonius Hospital , Nieuwegein , The Netherlands. 10. j Genetics , Radboud University Medical Center , The Netherlands. 11. k Gastro-Enterology and Hepatology , Erasmus University Medical Center , Rotterdam , The Netherlands. 12. l Surgery , Deventer Hospital , Deventer , The Netherlands. 13. m Radiology , University Medical Center Groningen , The Netherlands. 14. n Medical Oncology, Tergooi Hospital , Hilversum , The Netherlands. 15. o Gastro-Enterology , Radboud University Medical Center , Nijmegen , The Netherlands. 16. p Trial Office Imaging Division , UMC Utrecht , Utrecht , The Netherlands.
Abstract
BACKGROUND: Systematic evaluation and validation of new prognostic and predictive markers, technologies and interventions for colorectal cancer (CRC) is crucial for optimizing patients' outcomes. With only 5-15% of patients participating in clinical trials, generalizability of results is poor. Moreover, current trials often lack the capacity for post-hoc subgroup analyses. For this purpose, a large observational cohort study, serving as a multiple trial and biobanking facility, was set up by the Dutch Colorectal Cancer Group (DCCG). METHODS/ DESIGN: The Prospective Dutch ColoRectal Cancer cohort is a prospective multidisciplinary nationwide observational cohort study in the Netherlands (yearly CRC incidence of 15 500). All CRC patients (stage I-IV) are eligible for inclusion, and longitudinal clinical data are registered. Patients give separate consent for the collection of blood and tumor tissue, filling out questionnaires, and broad randomization for studies according to the innovative cohort multiple randomized controlled trial design (cmRCT), serving as an alternative study design for the classic RCT. Objectives of the study include: 1) systematically collected long-term clinical data, patient-reported outcomes and biomaterials from daily CRC practice; and 2) to facilitate future basic, translational and clinical research including interventional and cost-effectiveness studies for both national and international research groups with short inclusion periods, even for studies with stringent inclusion criteria. RESULTS: Seven months after initiation 650 patients have been enrolled, eight centers participate, 15 centers await IRB approval and nine embedded cohort- or cmRCT-designed studies are currently recruiting patients. CONCLUSION: This cohort provides a unique multidisciplinary data, biobank, and patient-reported outcomes collection initiative, serving as an infrastructure for various kinds of research aiming to improve treatment outcomes in CRC patients. This comprehensive design may serve as an example for other tumor types.
BACKGROUND: Systematic evaluation and validation of new prognostic and predictive markers, technologies and interventions for colorectal cancer (CRC) is crucial for optimizing patients' outcomes. With only 5-15% of patients participating in clinical trials, generalizability of results is poor. Moreover, current trials often lack the capacity for post-hoc subgroup analyses. For this purpose, a large observational cohort study, serving as a multiple trial and biobanking facility, was set up by the Dutch Colorectal Cancer Group (DCCG). METHODS/ DESIGN: The Prospective Dutch ColoRectal Cancer cohort is a prospective multidisciplinary nationwide observational cohort study in the Netherlands (yearly CRC incidence of 15 500). All CRCpatients (stage I-IV) are eligible for inclusion, and longitudinal clinical data are registered. Patients give separate consent for the collection of blood and tumor tissue, filling out questionnaires, and broad randomization for studies according to the innovative cohort multiple randomized controlled trial design (cmRCT), serving as an alternative study design for the classic RCT. Objectives of the study include: 1) systematically collected long-term clinical data, patient-reported outcomes and biomaterials from daily CRC practice; and 2) to facilitate future basic, translational and clinical research including interventional and cost-effectiveness studies for both national and international research groups with short inclusion periods, even for studies with stringent inclusion criteria. RESULTS: Seven months after initiation 650 patients have been enrolled, eight centers participate, 15 centers await IRB approval and nine embedded cohort- or cmRCT-designed studies are currently recruiting patients. CONCLUSION: This cohort provides a unique multidisciplinary data, biobank, and patient-reported outcomes collection initiative, serving as an infrastructure for various kinds of research aiming to improve treatment outcomes in CRCpatients. This comprehensive design may serve as an example for other tumor types.
Authors: Anke Richters; Richard P Meijer; Niven Mehra; Joost L Boormans; Antoine G van der Heijden; Michiel S van der Heijden; Lambertus A Kiemeney; Katja K Aben Journal: BMJ Open Date: 2021-05-18 Impact factor: 2.692
Authors: Z S Lalmahomed; R R J Coebergh van den Braak; M H A Oomen; S P Arshad; P H J Riegman; J N M IJzermans Journal: Cell Tissue Bank Date: 2017-03-03 Impact factor: 1.522
Authors: Joana B Neves; David Cullen; Lee Grant; Miles Walkden; Steve Bandula; Prasad Patki; Ravi Barod; Faiz Mumtaz; Michael Aitchison; Elena Pizzo; Veronica Ranieri; Norman Williams; William Wildgoose; Kurinchi Gurusamy; Mark Emberton; Axel Bex; Maxine G B Tran Journal: BMJ Open Date: 2019-06-11 Impact factor: 2.692
Authors: Rhode Bijlsma; Roel Wouters; Hester Wessels; Stefan Sleijfer; Laurens Beerepoot; Daan Ten Bokkel Huinink; Hester Cruijsen; Joan Heijns; Martijn P Lolkema; Neeltje Steeghs; Theo van Voorthuizen; Annelie Vulink; Els Witteveen; Margreet Ausems; Annelien Bredenoord; Anne M May; Emile Voest Journal: ESMO Open Date: 2020-04
Authors: Gabrielle Jongeneel; Marjolein J E Greuter; Natalia Kunst; Felice N van Erning; Miriam Koopman; Jan P Medema; Louis Vermeulen; Jan N M Ijzermans; Geraldine R Vink; Cornelis J A Punt; Veerle M H Coupé Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-06-23 Impact factor: 4.090
Authors: S J Schraa; K L van Rooijen; D E W van der Kruijssen; C Rubio Alarcón; J Phallen; M Sausen; J Simmons; V M H Coupé; W M U van Grevenstein; S Elias; H M Verkooijen; M M Laclé; L J W Bosch; D van den Broek; G A Meijer; V E Velculescu; R J A Fijneman; G R Vink; M Koopman Journal: BMC Cancer Date: 2020-08-20 Impact factor: 4.430
Authors: Jeroen W G Derksen; Anne M May; Lonneke V van de Poll-Franse; Belle H de Rooij; Dorothee A Hafkenscheid; Helena M Verkooijen; Miriam Koopman; Geraldine R Vink Journal: JNCI Cancer Spectr Date: 2021-05-13